Brokerages Set Zura Bio Limited (NASDAQ:ZURA) Target Price at $15.80

Shares of Zura Bio Limited (NASDAQ:ZURA - Get Free Report) have earned a consensus recommendation of "Buy" from the seven research firms that are presently covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company. The average twelve-month target price among brokerages that have issued ratings on the stock in the last year is $15.80.

Several research firms have issued reports on ZURA. HC Wainwright restated a "neutral" rating and issued a $5.00 price objective on shares of Zura Bio in a research note on Tuesday, December 24th. Leerink Partners started coverage on shares of Zura Bio in a report on Monday, November 4th. They issued an "outperform" rating and a $15.00 target price for the company. Leerink Partnrs raised shares of Zura Bio to a "strong-buy" rating in a report on Monday, November 4th. Cantor Fitzgerald reissued an "overweight" rating on shares of Zura Bio in a report on Wednesday, December 11th. Finally, Chardan Capital cut their price target on shares of Zura Bio from $14.00 to $12.00 and set a "buy" rating for the company in a report on Friday, November 8th.

Insiders Place Their Bets

In other news, Director Parvinder Thiara sold 1,001,633 shares of the stock in a transaction that occurred on Monday, November 25th. The shares were sold at an average price of $2.73, for a total value of $2,734,458.09. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. 22.10% of the stock is currently owned by company insiders.

Institutional Trading of Zura Bio

Several large investors have recently modified their holdings of the business. Great Point Partners LLC grew its position in shares of Zura Bio by 68.3% in the second quarter. Great Point Partners LLC now owns 4,642,241 shares of the company's stock valued at $16,248,000 after purchasing an additional 1,884,501 shares during the last quarter. Armistice Capital LLC grew its position in shares of Zura Bio by 53.2% in the second quarter. Armistice Capital LLC now owns 2,524,000 shares of the company's stock valued at $8,834,000 after purchasing an additional 876,000 shares during the last quarter. Braidwell LP acquired a new stake in shares of Zura Bio in the third quarter valued at approximately $10,040,000. Point72 Asset Management L.P. acquired a new stake in shares of Zura Bio in the second quarter valued at approximately $8,446,000. Finally, Geode Capital Management LLC grew its position in shares of Zura Bio by 70.6% in the third quarter. Geode Capital Management LLC now owns 912,625 shares of the company's stock valued at $3,706,000 after purchasing an additional 377,545 shares during the last quarter. 61.14% of the stock is currently owned by institutional investors and hedge funds.

Zura Bio Stock Performance

Shares of NASDAQ:ZURA traded down $0.03 during trading on Friday, hitting $1.77. The company's stock had a trading volume of 393,491 shares, compared to its average volume of 561,368. The business has a 50 day moving average price of $2.68 and a two-hundred day moving average price of $3.51. Zura Bio has a fifty-two week low of $1.76 and a fifty-two week high of $6.35.

Zura Bio (NASDAQ:ZURA - Get Free Report) last issued its earnings results on Thursday, November 7th. The company reported ($0.26) EPS for the quarter, missing analysts' consensus estimates of ($0.14) by ($0.12). As a group, equities analysts anticipate that Zura Bio will post -0.65 earnings per share for the current fiscal year.

Zura Bio Company Profile

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.